Novartis Says FDA Issues CRL For RLX030 For Acute Heart Failure - Quick Facts RTT News Novartis (NVS: Quote) said that the US Food and Drug Administration or FDA has issued a Complete Response Letter or CRL relating to the Biologics License Application or BLA for RLX030 to treat acute heart failure or AHF, stating that further evidence ... |
